Prevention

Although a once-daily pill to prevent HIV exists, US populations at highest risk have the lowest rates of usage.

In a new study, a pair of Australian virologists argue that we cannot predict virus outbreaks, looking at the “fault lines” of interaction between humans and animals may help us be better prepared.

An examination of broad-spectrum antibiotic use in this patient population is essential for developing strategies to mitigate the risk of these infections.

Remembering the links between infectious diseases such as influenza and HIV, among others, and mental health can improve patient outcomes.

James S. Lewis, PharmD, FIDSA, discusses the need for the development of non-antibacterial options against infections, such as monoclonal antibodies.

The growing threat of resistance and substantial costs for treating these infections accentuates the need for programs focused on appropriate treatment.

A new study gleans troubling findings—four in 10 health care providers choose to go to work despite experiencing symptoms of infectious disease.

Daniel Diekema, MD, explains how the microbiology lab works to provide optimal drug selection for empiric and directed therapy.

The US Food and Drug Administration (FDA) has cleared a complete blood cell count (CBC) test that, based on its categorization, can be run in more health care settings.

While a new FDA report shows antibiotic resistance remains low among many food-borne bacteria, some pathogens are increasingly showing multidrug resistance.

In case you missed them, we've compiled the top five infectious disease articles from this past week.

William Schaffner, MD, explains how health care providers can work towards getting patients who are aged 65 and older to receive a flu shot.

While rising temperatures and sea levels are often considered, changing climate patterns can have vast implications for epidemic risk as well.

Updated guidance from the CDC on Zika, candidemia infections in patients with C. difficile infections, and more topics made up our Top 5 articles for the month of October 2017.

Daniel Diekema, MD, explains why the microbiology laboratory should be a part of antimicrobial stewardship programs.

Dolutegravir seemed to be a promising maintenance monotherapy for people living with HIV, but the development of resistance mutations in testing strikes it from the list.

James S. Lewis, PharmD, FIDSA, explains why addressing issues surrounding antibiotic use in veterinary medicine is crucial in the fight against antibiotic resistance.

Researchers from The Scripps Research Institute have discovered why egg-based influenza vaccines offer a lower level of protection against H3N2 viruses.

The fast pace of biotechnology and an increasingly globalized world have changed the face of health security.

What is pharma doing about the impending antibiotic resistance “apocalypse?”

Part 3 of our series looks at

Three antimicrobial susceptibility tests have been cleared by the FDA concurrently with the launch of a new antibiotic Baxdela, to help guide its use.

At this year’s annual CHEST meeting, Theravance Biopharma investigators report positive new data pertaining to VIBATIV gleaned from the TOUR study.

Another prong in the battle against resistant Gram-negative infections is the addition of beta-lactamase inhibitors to restore or improve the activity of older carbapenems.

Investigators in China have found that the presence of the MCR-1 gene has increased in humans over a period of 5 years.